Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 14UNKNOWN 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Oxaliplatin 30Capecitabine 26Fluorouracil 20Irinotecan 19tislelizumab 18apatinib 16Paclitaxel 13Cisplatin 13S 1 (combination) 12Radiotherapy 12Leucovorin 11Bevacizumab 11Laparoscopy 9Drug Therapy 9Cetuximab 9sintilimab 8Endoscopic Mucosal Resection 8Radiation 7Gemcitabine 7Docetaxel 7camrelizumab 6XELOX 6Surgical Procedures, Operative 6Propranolol 6Nivolumab 6Neoadjuvant Therapy 6Immune Checkpoint Inhibitors 6Folfox protocol 6Levoleucovorin 5HMPL-013 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × nedaplatin × Gastrointestinal × Clear all
NCT07046221 2025-07-20

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Fujian Cancer Hospital

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡